AFP and hepatocellular carcinoma: Currently used clinical features and biomarkers, such as TNM staging system, BCLC staging system, and serum alpha-fetoprotein (AFP) level, were insufficient in providing accurate prognostic evaluation for HCC patients in clinical practice [4, 5].